Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression
出版年份 2019 全文链接
标题
Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression
作者
关键词
-
出版物
Science Translational Medicine
Volume 11, Issue 495, Pages eaaw2293
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2019-06-06
DOI
10.1126/scitranslmed.aaw2293
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T Cells
- (2019) Sema Kurtulus et al. IMMUNITY
- T cell stemness and dysfunction in tumors are triggered by a common mechanism
- (2019) Suman Kumar Vodnala et al. SCIENCE
- PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+T-Cell–Driven Antitumor Immunity
- (2018) Sarah L. Buchan et al. CLINICAL CANCER RESEARCH
- Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication
- (2018) Christopher C. Kloss et al. MOLECULAR THERAPY
- IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
- (2018) Keishi Adachi et al. NATURE BIOTECHNOLOGY
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- Eradication of spontaneous malignancy by local immunotherapy
- (2018) Idit Sagiv-Barfi et al. Science Translational Medicine
- Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
- (2018) Joseph A. Fraietta et al. NATURE
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
- (2018) Moshe Sade-Feldman et al. CELL
- CAR T-cell therapy of solid tumors
- (2017) Carmen S M Yong et al. IMMUNOLOGY AND CELL BIOLOGY
- Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
- (2017) Paul A. Beavis et al. JOURNAL OF CLINICAL INVESTIGATION
- Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells
- (2017) Daniel T. MacLeod et al. MOLECULAR THERAPY
- CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma
- (2017) Andras Heczey et al. MOLECULAR THERAPY
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
- (2017) Levi J. Rupp et al. Scientific Reports
- Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants
- (2017) Giedre Krenciute et al. Cancer Immunology Research
- CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells
- (2017) Yongping Zhang et al. Frontiers of Medicine
- Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors
- (2017) A. Kunert et al. OncoImmunology
- Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy
- (2017) Gail D. Sckisel et al. Journal for ImmunoTherapy of Cancer
- Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia
- (2016) Saad S. Kenderian et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Macrophage colony-stimulating factor receptor marks and regulates a fetal myeloid-primed B-cell progenitor in mice
- (2016) A. Zriwil et al. BLOOD
- Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL
- (2016) Annalisa D’Avola et al. BLOOD
- PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR
- (2016) Elise A. Chong et al. BLOOD
- T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells
- (2016) Ilaria Marigo et al. CANCER CELL
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
- (2016) Xiaojun Liu et al. CANCER RESEARCH
- L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
- (2016) Roger Geiger et al. CELL
- Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy
- (2016) Madhusudhanan Sukumar et al. Cell Metabolism
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction
- (2016) Nicole E. Scharping et al. IMMUNITY
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models
- (2016) Yuki Kagoya et al. JOURNAL OF CLINICAL INVESTIGATION
- S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate
- (2016) Petros A. Tyrakis et al. NATURE
- Driving CAR T-cells forward
- (2016) Hollie J. Jackson et al. Nature Reviews Clinical Oncology
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells
- (2016) Lenka V. Hurton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials
- (2016) Ricardo Costa et al. Oncotarget
- Novel TGF-β inhibitors ready for prime time in onco-immunology
- (2016) Armand de Gramont et al. OncoImmunology
- Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
- (2015) Soranobu Ninomiya et al. BLOOD
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
- (2015) Zeguo Zhao et al. CANCER CELL
- Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
- (2015) Ping-Chih Ho et al. CELL
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
- (2015) Chih-Hao Chang et al. CELL
- Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
- (2015) A. Yonezawa et al. CLINICAL CANCER RESEARCH
- Challenges and opportunities of allogeneic donor-derived CAR T cells
- (2015) Yinmeng Yang et al. CURRENT OPINION IN HEMATOLOGY
- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
- (2015) Nabil Ahmed et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
- (2015) D Sommermeyer et al. LEUKEMIA
- Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
- (2015) Kurt Schönfeld et al. MOLECULAR THERAPY
- Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression
- (2015) Kevin J Curran et al. MOLECULAR THERAPY
- Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction
- (2015) Ende Zhao et al. NATURE IMMUNOLOGY
- Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
- (2015) Bettina Weigelin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Targeting T cell metabolism for therapy
- (2015) David O'Sullivan et al. TRENDS IN IMMUNOLOGY
- Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition
- (2015) Maud Condomines et al. PLoS One
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
- (2013) L. B. John et al. CLINICAL CANCER RESEARCH
- Agonistic CD40 Antibodies and Cancer Therapy
- (2013) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function
- (2013) Madhusudhanan Sukumar et al. JOURNAL OF CLINICAL INVESTIGATION
- Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen
- (2013) Andrew L Doedens et al. NATURE IMMUNOLOGY
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
- (2012) H. J. Pegram et al. BLOOD
- Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice
- (2012) D. Chinnasamy et al. CLINICAL CANCER RESEARCH
- Agonistic Antibody to CD40 Boosts the Antitumor Activity of Adoptively Transferred T Cells In Vivo
- (2012) Chengwen Liu et al. JOURNAL OF IMMUNOTHERAPY
- OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+T cells
- (2012) Andreas A. Hombach et al. OncoImmunology
- CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
- (2011) D.-G. Song et al. BLOOD
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
- (2010) John A. Craddock et al. JOURNAL OF IMMUNOTHERAPY
- T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
- (2009) A. Di Stasi et al. BLOOD
- Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
- (2009) H. Harlin et al. CANCER RESEARCH
- Adoptive cell therapy for the treatment of patients with metastatic melanoma
- (2009) Steven A Rosenberg et al. CURRENT OPINION IN IMMUNOLOGY
- Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication
- (2009) Xiao-Song Zhong et al. MOLECULAR THERAPY
- Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells
- (2009) Luca Gattinoni et al. NATURE MEDICINE
- IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
- (2008) C. S. Hinrichs et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started